The completed deal sees CRO (contract research organization) Synteract takeover Munich-based Harrison Clinical Research to become SynteractHCR, creating a combined workforce of over 800 operating in 16 countries.
Speaking in January to Outsourcing-Pharma.com, a spokesman said that the acquisition was motivated by global expansion, allowing the company to have a “strong geographical presence in Western and Eastern Europe and an emerging presence in South America.”
Headquartered in San Diego, California, the company will offer its clients clinical support in drug development and managing Phase I-IV clinical trials across multiple therapeutic areas.